Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: A Pediatric Oncology Group study

P. D. Sadowitz, R. Dubowy, A. Souid, B. H. Pollock, H. Weinstein, R. T. Parmley, W. P. Bowman, V. Land, T. Vats, C. Pratt, G. R. Buchanan

Resultado de la investigación: Articlerevisión exhaustiva

2 Citas (Scopus)

Resumen

Purpose: The purpose of this phase I study was to determine the toxicities and response to continuous infusion carboplatin in combination with a fixed dose of etoposide (VP-16) in children with refractory acute leukemia. Patients and Methods: From January 1989 to February 1992, 20 patients received 28 courses of treatment. Each course of treatment consisted of a 1- hour intravenous (IV) infusion of VP-16 100 mg/m2/d for 5 days, followed by a 23-hour IV infusion of carboplatin each day. The initial, total 5-day dose of carboplatin (1,000 mg/m2) was escalated by 250- to 375-mg increments to a final, total dose of 1,875 mg/m2 over 5 days. Results: Significant marrow suppression was observed in all patients, with prolonged marrow aplasia at the 1,875-mg/m2 dose level. Grade III diarrhea occurred in three patients; 10 patients experienced life-threatening infection and three had severe thrombocytopenic bleeding. Major marrow responses (two complete remissions and two partial remissions) occurred in four patients (20%). Conclusion: In view of the apparent antileukemic efficacy and minimal extramedullary toxicity, carboplatin deserves further study in a phase II trial.

Idioma originalEnglish (US)
Páginas (desde-hasta)1969-1973
Número de páginas5
PublicaciónJournal of Clinical Oncology
Volumen12
N.º9
DOI
EstadoPublished - sept. 1994
Publicado de forma externa

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: A Pediatric Oncology Group study'. En conjunto forman una huella única.

Citar esto